I think on the balance of probability that the news will start...

I think on the balance of probability that the news will start to flow pretty soon the buying will pick up pace.

It's been a pretty lean 18 months with the exception of the fantastic PTX-100 data, of which the expanded and stretched again cohort will be closer to revealing more data building towards a possible registrational trial approval.

Biotech definitely requires patience and I think we may start to reap some dividends shortly.

I'm not expecting too much from the Thermo Fisher collaboration...Better to keep my expectations low and hope to be blown away.

But OmniCar as it stands without Thermo Fisher is a Ferrari and I can't wait to see the preclinical data start to hit as we approach phase 1 in the near future.

Cell Pryme is an awesome booster to our own programs, if we manage to commercialise on the journey it's a major bonus.

PTX-200? I'm expecting it to be shelved so we can concentrate funding into our other projects as they get closer to the clinic...OmniCar deal with Q-Cell will require large amounts of capital...The company is well funded but I'd still be managing frugally in today's environment...Steven is known for being frugal and maximising bang for buck which is great.

Should be a very exciting 6 months to come.